|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2006
Adult pulmonary Langerhans’ cell histiocytosis
Pulmonology Dept, Saint Louis Teaching Hospital, Paris, France.
CORRESPONDENCE: A. Tazi, Pulmonology Dept, Saint Louis Teaching Hospital, 1 avenue Claude Vellefaux, 75475, Paris cedex 10, France, Fax: 33 142499395. E-mail: abdellatif.tazi{at}sls.ap-hop-paris.fr
Keywords: Bronchoalveolar lavage, cytokines, dendritic cells, high-resolution computed tomography of the lung, histiocytosis, Langerhans’ cells
Received: February 25, 2004
Accepted November 9, 2004
Adult pulmonary Langerhans’ cell histiocytosis is a rare disorder of unknown aetiology that occurs predominantly in young smokers, with an incidence peak at 20–40 yrs of age. In adults, pulmonary involvement with Langerhans’ cell histiocytosis usually occurs as a single-system disease and is characterised by focal Langerhans’ cell granulomas infiltrating and destroying distal bronchioles.
High-resolution computed tomography (HRCT) of the chest is essential to the diagnosis, typically showing a combination of nodules, cavitated nodules, and thick- and thin-walled cysts. A high macrophage count in bronchoalveolar lavage (BAL) fluid is a common but nonspecific finding that merely reflects exposure to tobacco smoke. BAL is useful for eliminating infections and the other infiltrating lung disorders that can be seen in young adults. Langerhans’ cells can be identified in BAL fluid, but, in contrast to what was initially hoped, this test shows a very low sensitivity and is rarely useful in the diagnosis of the disease.
The definite diagnosis of pulmonary Langerhans’ cell histiocytosis requires identification of Langerhans’ cell granulomas, which is usually achieved by surgical lung biopsy at a site selected by chest HRCT. In practice, however, lung biopsy is performed on a case-by-case basis.
No effective treatment is available to date, and improved understanding of the mechanisms involved in the pathogenesis of pulmonary Langerhans’ cell histiocytosis is urgently needed, and should help in the development of specific therapeutic strategies for patients with this orphan disease.
This article has been cited by other articles:
|
|
 |
|
  K Windebank and V Nanduri Langerhans cell histiocytosis Arch. Dis. Child., November 1, 2009; 94(11): 904 - 908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Prasse, M. Stahl, G. Schulz, G. Kayser, L. Wang, K. Ask, J. Yalcintepe, A. Kirschbaum, E. Bargagli, G. Zissel, et al. Essential Role of Osteopontin in Smoking-Related Interstitial Lung Diseases Am. J. Pathol., May 1, 2009; 174(5): 1683 - 1691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Lynch III Rare Interstitial Lung Diseases: Pulmonary Langerhans Cell Histiocytosis, Lymphangioleiomyomatosis, and Cryptogenic Organizing Pneumonia ACCP Pulmonary Med Brd Rev, January 1, 2009; 25(0): 585 - 618. [Full Text] [PDF]
|
|
|
|
|
|
J. P. Lynch III Idiopathic Pulmonary Fibrosis, Nonspecific Interstitial Pneumonia/Fibrosis, and Sarcoidosis ACCP Pulmonary Med Brd Rev, January 1, 2009; 25(0): 635 - 686. [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Attili, E. A. Kazerooni, B. H. Gross, K. R. Flaherty, J. L. Myers, and F. J. Martinez Smoking-related Interstitial Lung Disease: Radiologic-Clinical-Pathologic Correlation1 RadioGraphics, September 1, 2008; 28(5): 1383 - 1396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Gadkowski and J. E. Stout Cavitary Pulmonary Disease Clin. Microbiol. Rev., April 1, 2008; 21(2): 305 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Ryu, C. E. Daniels, T. E. Hartman, and E. S. Yi Diagnosis of Interstitial Lung Diseases Mayo Clin. Proc., August 1, 2007; 82(8): 976 - 986. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |